A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.
Phase 1
- Conditions
- Healthy volunteersMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-509862-39-00
- Lead Sponsor
- Echo Pharmaceuticals B.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method